SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-054229
Filing Date
2021-11-04
Accepted
2021-11-04 07:06:05
Documents
14
Period of Report
2021-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fulc-8k_20211104.htm   iXBRL 8-K 34020
2 EX-99.1 fulc-ex991_6.htm EX-99.1 155435
3 GRAPHIC gkqcdvzpunl0000001.jpg GRAPHIC 2969
  Complete submission text file 0001564590-21-054229.txt   336398

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA fulc-20211104.xsd EX-101.SCH 5689
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20211104_lab.xml EX-101.LAB 19314
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20211104_pre.xml EX-101.PRE 11486
7 EXTRACTED XBRL INSTANCE DOCUMENT fulc-8k_20211104_htm.xml XML 3553
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 211377958
SIC: 2834 Pharmaceutical Preparations